Skip to content

The effect of Chinese herbal medicine Shugan Wendan Decoction for the treatment of H-type essential hypertension: a ranodmized controlled trial.

The effect of Chinese herbal medicine Shugan Wendan Decoction for the treatment of H-type essential hypertension

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2000003480
Enrollment
Unknown
Registered
2020-07-09
Start date
2020-07-31
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H-type essential hypertension

Interventions

Sponsors

Guangdong Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Blood pressure >= 130/80 mmHg and/or has been diagnosed with high blood pressure, and normal blood pressure after treatment (the treatment plan is Valsartan capsule 80mg qd), and Hcy >= 10µmol/L; 2. Comply with phlegm and blood stasis syndrome, and liver stagnation syndrome-those with the following 3 main syndromes or 2 main syndromes plus 2 or more secondary syndromes can be diagnosed: Main symptoms: (1) limbs are heavy and full of abdominal distension; (2) Tingling, pain has a fixed place; (3) Emotional depression or irritability, irritability, goodness and rest; Secondary evidence: (1)flank pain; (2) nausea and vomiting; (3) veins and ecchymosis (lips, gums, dark purple nails, red skin on the muscle surface);(4) The tongue is greasy or the tongue is dark purple or has ecchymosis, petechiae, and thick tongue veins; (5) pulse string or pulse string; (6) local sensory disturbance. 3. The age is 30~75 years old; 4. Those who agree to cooperate with the collection of data and improve relevant inspections; 5. Those who voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe cardiovascular and cerebrovascular diseases (such as cardiac insufficiency, acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.), liver and kidney dysfunction, mental disorders and other diseases; 2. Those who are unwilling to cooperate with data collection and blood drawing; 3. Women during pregnancy or lactation; 4. Patients who have used other antihypertensive drugs other than valsartan capsules or have high blood lipid levels and need to use lipid-lowering drugs; 5. Other circumstances that the researcher thinks are not suitable for participating in this research.

Design outcomes

Primary

MeasureTime frame
Homocysteine;blood pressure;

Countries

China

Contacts

Public ContactYanhong Chen

Guangzhou University of Chinese Medicine

13631404122@163.com+86 13631404122

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026